PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases.
IFNλ4
PD-1
cryoglobulinaemia
hepatitis virus C
hepatocellular carcinoma
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
14
02
2020
revised:
11
08
2020
accepted:
03
09
2020
pubmed:
17
9
2020
medline:
22
6
2021
entrez:
16
9
2020
Statut:
ppublish
Résumé
Genetic variants of IFNL4 and PDCD1 genes have been shown to influence the spontaneous clearance of hepatitis C virus (HCV) infection. We investigated the IFNL4 rs12979860 and the PDCD1 polymorphisms in 734 HCV-positive patients, including 461 cases with liver disease of varying severity and 273 patients with lymphoproliferative disorders to determine the association of these genes with patient's outcome. Expression levels of PDCD1 mRNA encoded by haplotypes were investigated by quantitative PCR in hepatocellular carcinoma (HCC) tissue and peripheral blood mononuclear cells. Flow cytometry was used to detect PD-1 and its ligand PD-L1. The frequency of IFNL4 rs12979860 C/T or T/T genotypes was significantly higher in patients with HCV-related diseases than blood donors (P < .0001). Patients expressing the IFNλ4 variant with one amino acid change that reduces IFNλ4 secretion was found increased in frequency in HCV-related diseases compared to HCC PDCD1 mRNA levels in HCC tissue were significantly higher in cases carrying the PD-1.3 A or the PD-1.7 G allele (P = .0025 and P = .0167). Linkage disequilibrium (LD) between PD-1.3 and IFNL4 was found in patients with mixed cryoglobulinaemia (MC) only (LD = 0 in HCC; LD = 72 in MC). PBMCs of MC patients expressed low levels of PD-L1 in CD19+IgM+B cells and of PD-1 in CD4+T cells suggesting the involvement of regulatory B cell-T cell interaction to the pathogenesis of MC. Collectively, our data indicate an important contribution of IFNλ4 expression to the development of HCV-related HCC and an epistatic contribution of IFNL4 and PDCD1 in MC. Studies of IFNL4 and PDCD1 genes are helpful to better understand the role of host genetic factors and immune antigens influencing the outcome of HCV-related diseases. Our data support an association between the expression of IFNλ4, which prevents the expression of IFNλ3, with all the different HCV-related diseases studied, and besides, evidence that a higher IFNλ4 expression is associated with hepatocellular at a younger age. The expression pattern of low PD-L1 on B cells and high PD-1 on CD4+T-cells in patients with HCV-positive cryoglobulinaemia suggests a critical role of the PD-1/PD-L1 signaling in modulating B cell-T cell interaction in this lymphoproliferative disease.
Sections du résumé
BACKGROUND
Genetic variants of IFNL4 and PDCD1 genes have been shown to influence the spontaneous clearance of hepatitis C virus (HCV) infection. We investigated the IFNL4 rs12979860 and the PDCD1 polymorphisms in 734 HCV-positive patients, including 461 cases with liver disease of varying severity and 273 patients with lymphoproliferative disorders to determine the association of these genes with patient's outcome.
METHODS
Expression levels of PDCD1 mRNA encoded by haplotypes were investigated by quantitative PCR in hepatocellular carcinoma (HCC) tissue and peripheral blood mononuclear cells. Flow cytometry was used to detect PD-1 and its ligand PD-L1.
RESULTS
The frequency of IFNL4 rs12979860 C/T or T/T genotypes was significantly higher in patients with HCV-related diseases than blood donors (P < .0001). Patients expressing the IFNλ4 variant with one amino acid change that reduces IFNλ4 secretion was found increased in frequency in HCV-related diseases compared to HCC PDCD1 mRNA levels in HCC tissue were significantly higher in cases carrying the PD-1.3 A or the PD-1.7 G allele (P = .0025 and P = .0167). Linkage disequilibrium (LD) between PD-1.3 and IFNL4 was found in patients with mixed cryoglobulinaemia (MC) only (LD = 0 in HCC; LD = 72 in MC). PBMCs of MC patients expressed low levels of PD-L1 in CD19+IgM+B cells and of PD-1 in CD4+T cells suggesting the involvement of regulatory B cell-T cell interaction to the pathogenesis of MC.
CONCLUSION
Collectively, our data indicate an important contribution of IFNλ4 expression to the development of HCV-related HCC and an epistatic contribution of IFNL4 and PDCD1 in MC.
LAY SUMMARY
Studies of IFNL4 and PDCD1 genes are helpful to better understand the role of host genetic factors and immune antigens influencing the outcome of HCV-related diseases. Our data support an association between the expression of IFNλ4, which prevents the expression of IFNλ3, with all the different HCV-related diseases studied, and besides, evidence that a higher IFNλ4 expression is associated with hepatocellular at a younger age. The expression pattern of low PD-L1 on B cells and high PD-1 on CD4+T-cells in patients with HCV-positive cryoglobulinaemia suggests a critical role of the PD-1/PD-L1 signaling in modulating B cell-T cell interaction in this lymphoproliferative disease.
Identifiants
pubmed: 32937024
doi: 10.1111/liv.14667
pmc: PMC7839592
doi:
Substances chimiques
IFNL4 protein, human
0
Interleukins
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
133-149Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Blood. 2000 Nov 15;96(10):3578-84
pubmed: 11071657
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
J Med Genet. 2010 Jan;47(1):54-8
pubmed: 19581275
Curr Opin Immunol. 2017 Oct;48:61-67
pubmed: 28865357
Cell Immunol. 2016 Dec;310:27-41
pubmed: 27660198
Front Immunol. 2018 Aug 23;9:1924
pubmed: 30190721
Nature. 2006 Feb 9;439(7077):682-7
pubmed: 16382236
Immunol Res. 2016 Apr;64(2):412-23
pubmed: 26286967
Haematologica. 2017 Jan;102(1):30-42
pubmed: 27884973
Oncotarget. 2016 Aug 23;7(34):54253-54262
pubmed: 27276713
Onco Targets Ther. 2016 May 30;9:3249-57
pubmed: 27313470
J Hepatol. 2015 Nov;63(5):1103-10
pubmed: 26186989
Gastroenterology. 2019 Apr;156(5):1496-1507.e7
pubmed: 30593799
Medicine (Baltimore). 2016 Oct;95(40):e4423
pubmed: 27749524
Pathol Res Pract. 2018 Nov;214(11):1758-1764
pubmed: 30249505
Cancer. 2016 May 1;122(9):1312-37
pubmed: 26959385
BMC Genomics. 2007 Jul 18;8:243
pubmed: 17640361
Nat Rev Immunol. 2013 Jun;13(6):412-26
pubmed: 23681096
Arthritis Rheum. 2005 Apr;52(4):1058-62
pubmed: 15818672
Oncotarget. 2016 Jun 21;7(25):37487-37497
pubmed: 27183918
Biomed J. 2019 Aug;42(4):243-251
pubmed: 31627866
Front Immunol. 2018 Jul 30;9:1774
pubmed: 30105035
Arthritis Rheum. 2009 Jan;60(1):207-18
pubmed: 19116915
Gastroenterology. 2007 Mar;132(3):1205-7
pubmed: 17383452
PLoS Pathog. 2018 Oct 11;14(10):e1007307
pubmed: 30308076
Tissue Antigens. 2003 Dec;62(6):492-7
pubmed: 14617032
Medicine (Baltimore). 2013 Sep;92(5):245-256
pubmed: 23982056
Hepatology. 2007 Mar;45(3):588-601
pubmed: 17326153
PLoS One. 2016 Mar 31;11(3):e0152448
pubmed: 27031235
Infect Genet Evol. 2015 Jun;32:89-96
pubmed: 25747035
Genes Immun. 2016 Jul;17(5):265-75
pubmed: 27278127
Chronic Dis Transl Med. 2018 Mar 12;4(1):29-44
pubmed: 29756121
World J Gastroenterol. 2016 Jul 28;22(28):6469-83
pubmed: 27605882
Nat Genet. 2017 May;49(5):795-800
pubmed: 28394349
J Virol. 2007 Apr;81(8):4215-25
pubmed: 17287266
Blood. 2010 Jul 22;116(3):343-53
pubmed: 20308602
Oncotarget. 2017 Jun 13;8(24):39198-39208
pubmed: 28487496
Cancer Biomark. 2018 Feb 6;21(2):287-297
pubmed: 29171986
CA Cancer J Clin. 2016 May;66(3):182-202
pubmed: 26766789
Infect Genet Evol. 2013 Mar;14:240-6
pubmed: 23291409
World J Gastroenterol. 2011 Jul 28;17(28):3322-9
pubmed: 21876620
Medicine (Baltimore). 2016 Dec;95(52):e5749
pubmed: 28033288
Nat Genet. 2002 Dec;32(4):666-9
pubmed: 12402038
Genes Immun. 2015 Jul-Aug;16(5):321-9
pubmed: 26020282
Nat Genet. 2013 Feb;45(2):164-71
pubmed: 23291588
Cancer Genet. 2016 Sep;209(9):365-375
pubmed: 27751353
Hum Immunol. 2010 Dec;71(12):1209-13
pubmed: 20837075
Immunol Lett. 2014 Nov;162(1 Pt A):212-6
pubmed: 25218665
Gastroenterology. 2010 Feb;138(2):682-93, 693.e1-4
pubmed: 19800335
Rheumatology (Oxford). 2007 Apr;46(4):572-8
pubmed: 17317717
PLoS Pathog. 2018 Nov 28;14(11):e1007420
pubmed: 30485383
Liver Int. 2010 Oct;30(9):1379-86
pubmed: 20738778
J Orthop Sci. 2013 Jul;18(4):514-8
pubmed: 23620109
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Clin Exp Immunol. 2009 Jan;155(1):1-15
pubmed: 19076824
Liver Int. 2021 Jan;41(1):133-149
pubmed: 32937024
J Clin Lab Anal. 2019 Jun;33(5):e22876
pubmed: 30843304
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Cancer Immunol Immunother. 2005 Apr;54(4):307-14
pubmed: 15599732
Nat Commun. 2015 Jan 22;6:5997
pubmed: 25609381
EMBO J. 2013 Nov 27;32(23):3055-65
pubmed: 24169568
Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):15001-6
pubmed: 23980172
J Interferon Cytokine Res. 2019 Oct;39(10):599-608
pubmed: 31070498
Eur J Immunol. 2004 Jan;34(1):126-36
pubmed: 14971038
Medicine (Baltimore). 2016 May;95(21):e3760
pubmed: 27227944
Int J Mol Sci. 2017 Dec 23;19(1):
pubmed: 29295527
Elife. 2019 Sep 03;8:
pubmed: 31478835
Gynecol Oncol. 2017 Jan;144(1):140-145
pubmed: 27836206
Gene. 2018 Jul 20;664:168-180
pubmed: 29705128
Asian Pac J Cancer Prev. 2018 Mar 27;19(3):693-698
pubmed: 29580042
Front Immunol. 2017 Oct 31;8:1434
pubmed: 29163507
Nat Genet. 2009 Oct;41(10):1105-9
pubmed: 19749757
Nat Rev Clin Oncol. 2017 Apr;14(4):203-220
pubmed: 27805626
Immunogenetics. 2018 Feb;70(2):73-86
pubmed: 28642997
Nat Commun. 2014 Dec 23;5:5699
pubmed: 25534433
Clin Cancer Res. 2018 Apr 1;24(7):1518-1524
pubmed: 29138342
J Virol. 2007 Mar;81(6):2545-53
pubmed: 17182670
Gene. 2012 Dec 15;511(2):308-13
pubmed: 23041554
Curr Opin Immunol. 2010 Apr;22(2):223-30
pubmed: 20207527
J Cancer Res Clin Oncol. 2015 Sep;141(9):1533-44
pubmed: 25604582